anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
FIELD: medicine. ^ SUBSTANCE: invention relates to field of medicine. Claimed invention relates to method and composition for treatment of central nervous system (CNS) disorder by intranasal application of compounds, which induce RNA interference. Composition by the invention contains molecules of short interfering nucleic acids (siPHK). Disorder is selected from dementia, Alzheimer&#39;s disease, Huntington&#39;s disease and/or Parkinson&#39;s disease, as well as congenital diseases associated with mutations in CNS genes. According to the invention method includes introduction to patient in case of necessity of efficient amount of one or more siPHK in accordance with the invention. ^ EFFECT: invention ensures suppression of expression of target genes, connected with changed CNS states. ^ 20 cl, 4 ex, 8 dwg
The present invention relates to a novel lipid-polymer hybrid MP/MMT composite with high drug entrapment efficiency (&gt; 60%), prepared and characterized by size, zeta potential, XRD, FT-IR, SEM, and rheological behavior. The degree of interaction between MMT and MP clay estimates by XRD experiments and the results are strongly pH-dependent. The SEM images presented a novel system with a raspberry-like structure, absorbing MMT on the surface of the PM mainly by electrostatic attraction. The results of the rheological tests support that the elasticity of the said compound depends on the pH and that at Ph=PI the compound has a highly elastic structure based on a continuous network (house-of-cards). Preliminary cytotoxicity studies show qualitatively that the prepared systems are not toxic. Finally, the MP and MP/MMT systems exhibit controlled release of AT over 48 hours with a pH-dependent drug release and rate mechanism. Said novel compound is a simple and low-cost drug delivery system a imed at controlled intestinal-colonic release.
FIELD: medicine, pharmacy. SUBSTANCE: invention relates to application of colostrinin as a drug in treatment of chronic disorders of central nervous system, immune system, neurological, mental disorders, feeble-mindedness, neurodegenerative diseases, Alzheimer&#39;s disease, motoneuron disease, for treatment of psychosis or neurosis as a dietetic supplement. Invention relates also to pharmaceutical composition containing colostrinin, dietetic supplement and nanopeptide. Invention provides the realization of indicated designation. EFFECT: valuable medicinal properties of drug. 24 cl, 3 tbl, 1 dwg, 10 ex
&lt;P&gt;PROBLEM TO BE SOLVED: To provide nucleic acids encoding vespid venom enzymes, or fragments thereof, to provide products expressing the nucleic acids, or fragments thereof, and to provide use thereof.  &lt;P&gt;SOLUTION: The nucleic acids encoding vespid venom enzymes, or fragments thereof, recombinant vectors comprising such nucleic acids, and host cells containing the recombinant vectors are disclosed. The expression of such nucleic acids to produce recombinant vespid venom enzymes, or recombinant fragments, derivatives or analogs thereof are disclosed. Such recombinant products are useful for diagnosis of allergy and for therapeutic treatment of allergy. In specific embodiments, the nucleic acids encoding, and complete nucleotide sequences and amino acids sequences for, vespid venom phospholipase such as Dolichovespula maculata phospholipase and Vespula vulgaris phospholipase, and vespid venom hyaluronidase such as Dolichovespula maculata hyaluronidase.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method for searching a lymphocyte chemoattractant factor and a method for using the same.  &lt;P&gt;SOLUTION: The purified DNA encoding a LCF and the recombinant protein expressed from such DNA are disclosed. The LCF fragment or analog exhibits a LCF agonist or antagonist activity. The method for suppressing a LCF-CD4 interaction and the method for screening a candidate LCF agonist or antagonist are provided. The composition and a method useful for stimulating proliferation of CD4&lt;SP&gt;+&lt;/SP&gt;T-cell in a mammal are also provided.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a new human immune response regulatory protein, its gene and antibody and a pharmaceutical composition using them.  &lt;P&gt;SOLUTION: The human immune response regulatory protein has a specific amino acid sequence or a sequence in which one or a plurality of amino acid residues are deleted, added or substituted with other amino acid residues in the amino acid sequence. The specific base sequence encodes the protein. The antibody specifically recognizes the protein. The pharmaceutical composition for immune-related diseases including cancer, allergy, autoimmune disease and inflammatory disease is obtained by using them.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
PROBLEM TO BE SOLVED: To obtain an emulsion of a W/O/W three-phase type in which water exists in the aqueous phase having relatively high water activity to sustain the efficacy of the active ingredients without decomposition. SOLUTION: In an emulsion of a W/O/W three-phase type comprising the outer water phase and the oil phase constituting the water-in-oil primary emulsion, either the outer water phase or the inner water phase is allowed to have the water activity of &lt;=0.85. An effective amount of polyol is preferably added to the hydrogen having &lt;=0.85 of water activity. The effective amount means 35-90wt.% of the total weight of the water phase. The polyol is, for example, glycerol or acrylic polymer. In addition, silicone oil and a silicone emulsifier may be added to the oil phase. This emulsion is useful as a stable medium in cleaning and caring of skin, mucous membrane and keratin fibers.
This invention relates to a cacti polyose sulfuric ester possessing biological activity, and its application. The sugar chain composed by glucose, galactose, xylose, arabinose, connect by 1-&gt;6 (or un- reduction terminal), 1-&gt;4 and 1-&gt;3 glycosidic bond. It takes plant cacti (Opuntia dillenii Haw.) polyose as matetials, by sulphonating agent hand ling obtained. The esterification degree of sulfuric is 0.5 to 2.5, sulphonating agent composed by chlorosulfonic acid and pyridine by volume ratio of 1:2 to 8. This cacti polyose sulfuric ester not only possess higher degree of substitution, furthermore possess rather strong activity of human humanimmunodeficiencyvirus and herpes simplex virus resisting. It has low toxicity to human cell, useful for preparing drug for prevention or treatment of human HIV and herpes simplex virus infection.
A method of preventing the precipitation of hormone preparations within drug delivery systems that depend on the fluidity of the infusate for proper function. A non-toxic water soluble detergent is dissolved in the hormone solution prior to the introduction of the solution into the drug delivery system. The detergent is added in amount sufficient to prevent precipitation of the hormone during long-term storage in the drug delivery device. According to one form of usage, the hormone-detergent solution is charged to the pressurized drug storage chamber of an implanted infusion pump by injection through the patient&#39;s skin. As the solution is discharged from the delivery device by the constant pressure exerted upon the storage chamber, its low rate of flow is controlled by a restricted fluid passage. The solution is conveyed to an infusion site and diluted by the blood stream.
Aziridines may be subjeted to a cyclooligomerization reaction to produce polyazacycloalkane compounds useful for example in the preparation of chelating agents for use in diagnostic imaging contrast agents. N-benzyl-aziridine in particular is useful as it can be cyclotetramerized and debenzylated to yield cyclen, a key intermediate in chelating agent preparation. The invention provides a particularly attractive route to production of N-benzyl and other N-arylmethyl aziridines of formula (I)where each R1 is independently hydrogen or a group AR and Ar is an optionally substituted phenyl group. The process comprises reacting a purified N-arylmethylethanolamine-sulphonate sulphonate ester with a base. N-aryimethyl-ethanolamine sulphonate ester of the formula R&#39;NHCH2CH2OSO3H, wherein the N-arylmethyl group R&#39; is an N-(bisarylmethyl) or N-(triarylmethyl) group, as intermediates. In a further aspect, the invention provides compounds of formula (II)where Ar and R1 are as hereinabove defined and at least two differing ArCHR21 moieties are present.
PURPOSE: To enable hypoxia and ischemic disease in a central nerve system to be treated, by providing a reservoir to store nutrient fluid to be oxygenated, a means for oxygenating and preparing the fluid, and a means for injecting an oxygenated fluid into a human&#39;s extravascular route, excreting, and circulating. CONSTITUTION: Nutrient emulsion is accepted in a reservoir 10 for nutrient emulsion, injected into a cerebrospinal route after processes of pH-regulation and filtration 12, temperature control 14, oxygenation 16, and pressure and flow velocity control 18, and supplied to the lateral ventricle 20 of a human&#39;s brain 22. By these processes, the oxygenated nutrient emulsion touches to a subarachnoid cavity, small Virchow- Robin spaces, and so on. As the lateral ventricle 20 is connected to the other parts of the cerebrospinal route through the fluid, the fluid is withdrawn from a spinal subarachnoid space 26 or a cerebrum 24, so that a circulation is completed. The withdrawn fluid is sent to a means 28 for collecting excreta, and the chemical or physical properties of the excreta are monitored by an excreta monitor 34.  Subsequently, a diagnostic fluid, which is sterilized and reconstructed in the process 23, is supplied to the reservoir 10.
PCT No. PCT/SE94/00291 Sec. 371 Date May 25, 1994 Sec. 102(e) Date May 25, 1994 PCT Filed Mar. 31, 1994 PCT Pub. No. WO94/25039 PCT Pub. Date Nov. 10, 1994Cholestyramine and starch containing, oil-free compositions with excellent organoleptic features are obtained by mixing cholestyramine and grain starch in a weight ratio of 1:1.8 to 2.9 with the addition of grain bran as a filler and optionally an aroma stuff with 10 to 35% by weight of water (calc. on the starting materials) into a homogenous moist mass, forming of the mass through extrusion into a string, whereby the temperature is 105 DEG -180 DEG  C. (measured in the mass in the extrusion head) and the pressure is 30-70 bars (measured in the extrusion head), and subsequently drying at a temperature above 100 DEG  C. to a remaining humidity of &lt;/=3.5% by weight, whereby the extruded material before or after the drying is divided into bars or is grinded into a powder.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide nucleic acids, proteins, antibodies and mimics regulating cellular physiological functions, development, differentiation or functions in various cell types including hematopoietic cells.  &lt;P&gt;SOLUTION: There are disclosed CTLA-8-related antigens derived from mammals. There are also disclosed reagents relating to CTLA-8-related antigens derived from mammals including purified proteins, specific antigens, and nucleic acids encoding the antigens. The reagents and diagnostic kits are also provided including instructions about a polypeptide derived from matured coding sections of a specific base sequence and the use of coupling compounds for detection or instructions about disposing the coupling compounds or other reagents of this kit. A method for using them is provided.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
The present invention relates to nucleic acids encoding SID.RTM. polypeptide s which are encoded by a said nucleic acids. The invention also concerns vecto rs comprising a nucleic acid encoding a SID.RTM. polypeptide as well as host cells transformed with such vectors. The invention is also directed to two- hybrid methods which make use of the nucleic acids encoding a SID.RTM. polypeptide selected from a pathogenic strain of the hepatitis C virus as we ll as to methods for selecting molecules which inhibit the binding between a SID.RTM. polypeptide and a polypeptide which specifically binds thereto.&lt;/SD OAB&gt;
The present invention is based on the key roles played by Hedgehog proteins in the regulation of homeostasis of the adult intestinal epithelium. Ihh is expressed in the adult mammalian colon and provides a lineage-instructive signal and regulates colonic epithelial morphogenesis in a compartmental fashion. Loss of Ihh expression precedes morphological change in colon tumorigenesis, i.e. carcinogenesis, and Ihh was absent in HT-29 colon carcinoma cells. Treatment of cancerous HT-29 cells with exogenous Hedgehog protein restored their differentiation. Ihh thus plays a pivotal role in the maintenance of colonic epithelial homeostasis in the differentiation of the GI tract cells and is essential for the enrolment of these GI tract cells on the Death program thus maintaining homeostasis to avoid or treat carcinogenesis. In addition, in gastric cancer expression of Shh is lost and loss of Shh expression precedes morphological changes in the parietal cells of the stomach. Shh is specifically expressed in fundic glands as well as in gastric heterotopia in the esophagus in Meckel&#39;s diverticulum. Shh thus has a unique role as a morphogen in fundic gland homeostasis. The present invention relates to methods in which a source of Hedgehog proteins is used prophylactically or therapeutically to maintain homeostasis of the adult intestinal epithelium. In particular the invention relates methods whereby sources of Hedgehog protein are used to prevent or treat carcinogenesis in adult gastric and colonic tissues. The invention also relates to Hedgehog-based method of diagnosing susceptibility for or the presence of carcinogenesis in the adult GI tract, particularly in gastric and colonic tissues. The invention further provide for compositions to be used in the Hedgehog-based methods of diagnosing, preventing and treating epithelial tumorigenesis in the adult GI tract.
Nutritional knowledge is among the factors that affect individuals\&#39; eating habits and diet quality. Food consumption is rewarding in itself as it increases energy and eliminates hunger (an unpleasant sensation); however, daily experiences show that people often eat without hunger. Individuals with high body awareness are expected to be aware of the changes occurring in their body and to change these changes. In the project, nutrition knowledge level, reward-related eating behaviour and body awareness will be compared according to gender in healthy young adults, and all these values will be evaluated through scales. The study data will be collected with a single interview by face-to-face interview method. Each participant will be informed about the study and their written and verbal consent will be obtained. The application time of the questionnaires is expected to take approximately 10 minutes for each participant. In case of a difference between genders for the values investigated, it is aimed to develop individuals\&#39; awareness of these situations. In addition, the relationship between these situations will also be evaluated. It is aimed to create awareness for the situations that are found to be related.
PURPOSE:To obtain the germ-free reduced pressure package which prevents the segregation of a germ-free powder mixture arising from vibration, etc., by sealing the above-mentioned powder mixture into the package under the specific condition of vacuum degree. CONSTITUTION:The vacuum degree at the time of reduced pressure packaging is &lt;=600mmHg. The vacuum degree is preferably set at 200 to 400mmHg by taking the degree of damage of a packing material, etc., into consideration when the package is going to be placed under long-term vibration. The germ- free reduced pressure package is formed by a method of packaging, under a reduced pressure, the germ-free powder mixture, which is uniformly mixed into the packing material at &lt;=600mmHg vacuum degree by using a vacuum packaging machine under a germ-free condition. The formation of the germ-free reduced pressure package by using the germ-free powder mixture previously subjected to the reduced pressure packaging is possible as well. The packing material can be sterilized by various kinds of sterilization methods, for example, gammarays and gaseous ethylene oxide, according to need.
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: nutritional and pharmaceutical composition in form of baby food contains fat, protein and carbohydrate components and includes milk serum and casein with weight ratio of casein to serum from 1:1 to 1:2.4. They contain, at least: 3 g of arginine per 100 g of protein, from total content of fatty acids: 10 wt % of linoleic acid, 1 wt % of alpha-linoleic acid, one long-chain polyunsaturated fatty acid, selected from group, consisting of docosahexaenic, arachidonic and eicosapentaenoic acid, to 25 wt %, at least one polyunsaturated fatty acid and 2-12 g of indigestible oligosaccharides with polymerisation degree from 2 to 100 per 100 g of dry weight of said composition, as well as neutral and acidic oligosaccharides, containing units of uronic acid. Pharmaceutical composition is applied in treatment and/or prophylaxis of inflammatory disease, diarrhea, eczema and/or atopic dermatitis. Prevention of allergy or diarrhea is performed by introduction of composition to child enterally or perorally. ^ EFFECT: inventions ensure stimulation of immune system maturing and development in babies of intestine and intestinal flora, similar to flora, obtained during breast feeding, optimal feeding, prevents penetration of allergens into general blood circulation and reduces risks associated with feeding with baby&#39;s formula based on milk serum. ^ 17 cl, 4 tbl, 3 ex
The invention discloses a medicine for treating a piglet edema disease and a preparation method thereof. The medicine is prepared from luisia morsei, loosestrife, chinaroot greenbrier, all-grass of twocolor velvetplant, pilea cavaleriei, abelmosk, Chinese starjasmine stems, cordate houttuynia, acmella ciliate, polygala tenuifolia, sweet basil, herb of dewberryleaf cinquefoil, oxalis rubra, Acorus gramineus Soland. var. pusillus Engl., f. suaveolens C. Y. Cheng, mss., ardisia japonica, inula cappa, Chinese alpine rush, tanoak bark, flower of Aglaia odorata Lour., Neolitsea chuii seeds, cardinal flower, Circaea lutetiana Linn. subsp. quadrisulcata (Maxim.)Asch.&amp; Magnus, agilawood, henry clematis root, cortex acanthopanacis, hairyvein agrimony and Chinese dates. The medicine has the advantages that treatment principles are removing toxicity for detumescence and freeing lung for diuresis, the auxiliary principle is invigorating spleen to eliminate dampness, the treatment effect on the piglet edema disease is significant, the resistance ability of piglets can be enhanced, the treatment course is short, the treatment effect is good, medicine tolerance is avoided, no medicine residue exists, and the medicine is safe, convenient to use, easy to prepare, low in cost and capable of effectively controlling the illness state.
PURPOSE: A pharmaceutical composition containing a Magnoliae Cortex extract as an effective ingredient is provided. Therefore, the composition is used as a prophylactic and therapeutic agent for treatment of cerebral disease caused by neuronal death caused by brain ischemia because it has excellent neuronal death inhibitory action and has no toxicity to human body. CONSTITUTION: Magnolia officinale Rehder et Wiles. is extracted in water, low alcohol, hexane, ethyl acetate or a mixture thereof, concentrated and then freeze dried. The pharmaceutical composition containing the Magnoliae Cortex extract is effective for prevention and treatment of cerebral disease selected from the group consisting of cerebral apoplexy, Parkinson&#39;s disease, senile dementia and Huntington&#39;s chorea. For example, 1kg Magnoliae Cortex is extracted with 2L methanol aqueous solution with a sonicator two times to produce 3L extract, which is filtered, concentrated, resulting in an average yield of 5% or more.
1313207 Preparing 7-amino-cephalosporanic acid; N-haloalkanoylcephalosporins ELI LILLY &amp; CO 24 June 1970 [26 June 1969] 30753/70 Heading C2A [Also in Division C3] 7-Amino-cephalosporanic acid is prepared from cephalosporin C by acylating the amino group in the adipamyl side chain with an α- halo- or α,α-dihalo-C 2 to C 4 alkanoyl group, protecting the carboxyl groups, treating with a halogenating agent to convert the amido group in the 7-position to an imino halide, converting the imino halide to an imino ether, hydrolysing the imino ether and if necessary, removing the carboxyl-protecting groups, to give 7-aminocephalosporanic acid. The amino group is preferably acylated with a chloroacetyl group, suitably while the cephalosporin C is still in the preparative fermentation broth. The N-haloalkanoyl derivative is extracted with waterimmiscible solvent (e.g. alkyl esters preferably with 1/10 volume of alkanol) and precipitated from the extract as a salt. The preferred salt is an amine salt, since the subsequent reaction for protecting the carboxyl groups proceeds more rapidly with better yields if an amine salt is used. The carboxyl groups arc protected by esterification, preferably as a silyl ester by treatment with an alkylchlorosilane. The imino halide is formed by reaction with a halogenating agent such as a chloride or oxychloride of phosphorus, sulphur or carbon, preferably phosphorus pentachloride, and is converted to the imino ether by reaction with an alcohol, a phenol or a sulphydryl compound, e.g. npropanol. The imino ether is hydrolysed or alcoholysed by treatment with water or an alcohol under mildly acidic or basic conditions; this treatment may also remove the carboxylprotecting ester groups, or alternatively they may be removed by other conventional procedures, e.g. hydrogenolysis. Novel N - α - haloalkanoyl cephalosporins having the formula wherein R is an α-halo- or α,α-dihalo-C 2 to C 4 alkanoyl group and X is hydrogen or C 1 -C 4 alkyl, C 4 -C 8 t-alkyl, C 5 -C 8 t-alkenyl, C 5 -C 8 talkynyl, phenacyl, trichloromethyl, benzyl, benzhydryl, p-methoxybenzyl, p-nitrobenzyl, trityl, trimethylsilyl, dimethylsilyl, methylsilyl, triethylsilyl, diethylsilyl, or ethylsilyl, and the alkali metal, alkaline earth metal, quinoline, cyclohexylamine, 5-ethyl-2-methylpyridine, 2-, 3- or 4-picoline, N-ethyl or N-methylmorpholine, 2,6-lutidine, N,N-diethylcyclohexylamine, hexamethylenetetramine, N,N - dimethylbenzylamine or N,N-dibenzylethylenediamine salt thereof when one or both X groups are hydrogen, are prepared by treating cephalosporin C with an appropriate haloacyl halide or mixed anhydride and if required, salifying the product. Reference has been directed by the Comptroller to Specification 1,041,985.
[GB1313207A]
PURPOSE:To produce the titled glass free internal defect, having excellent mechanical properties, and suitable as a ceramic for living body, e.g. a dental material, etc., by vitrifying a calcium phosphate composition added with a specific crystals, and crystallizing the glass. CONSTITUTION:A crystal having the same composition as the calcium phosphate composition used as the main component or a calcium phosphate crystal having higher melting point than the above composition is used as a nucleating agent. A mixture of (A) 100pts.wt. of a calcium phosphate composition [the atomic ratio (Ca/P) is 0.35-1.7] and (B) &lt;=95pts.wt. of above crystal is melted by heating, molded to a desired form, placed in a heating apparatus, and heat-treated at a temperature below the melting point of the glass (i.g. about 500-800 deg.C) at a heating rate of about 50-200 deg.C/hr for about 0.5-100hr to effect the uniform crystallization throughout the matrix glass.